Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.

about

Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.

Item

http://www.wikidata.org/entity/Q47663088

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Pharmacological Prevention of ...... tablished and Emerging Agents.

@en

Pharmacological Prevention of ...... tablished and Emerging Agents.

@nl

type

Item

label

Pharmacological Prevention of ...... tablished and Emerging Agents.

@en

Pharmacological Prevention of ...... tablished and Emerging Agents.

@nl

prefLabel

Pharmacological Prevention of ...... tablished and Emerging Agents.

@en

Pharmacological Prevention of ...... tablished and Emerging Agents.

@nl

P1476

Pharmacological Prevention of ...... tablished and Emerging Agents.

@en

P2093

David R Saxon

http://www.w3.org/2001/XMLSchema#string

Neda Rasouli

http://www.w3.org/2001/XMLSchema#string

Robert H Eckel

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Next generation of weight management medications: implications for diabetes and CVD risk

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus tre

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

P2888

s40265-017-0857-3

P304

203-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0857-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29305768

http://www.w3.org/2001/XMLSchema#string